VIDA Ventures is a venture capital firm focused on biomedical innovations.

VIDA Ventures

Vida Ventures is a next-generation life sciences investment firm founded in 2017 by a group of scientists, physicians, entrepreneurs and investors passionate about building and funding breakthroughs in biomedicine. Together we form an independent, bold investment group bound together by a simple word – life. Our mission is to bring science to life and advance transformative biomedical innovations that have the potential to make a meaningful difference for patients. Vida has a bicoastal presence and currently manages approximately $1.8 billion.

LianBio

Dyne Therapeutics

Allogene Therapeutics

Neogene Therapeutics

Oyster Point Pharmaceuticals

Praxis Precision Medicines

Asklepios BioPharmaceutical

Centessa Pharmaceuticals

Homology Medicines

Kinnate Biopharma

Sutro Biopharma

Vigil Neuroscience

Kronos Bio

Vida Ventures, LLC

Tectonic Therapeutic, Inc. is now a public company (Nasdaq: TECX)! An important milestone on their way to advancing biologics that overcome the existing challenges of GPCR-targeted drug discovery. Learn more: https://bwnews.pr/4exzhW4 #VidaPortfolio

Today, Vigil Neuroscience announced a $40 Million strategic investment from Sanofi, further validating Vigil’s promising precision medicine approach. Congratulations, Vigil team! Learn more: https://bit.ly/4cmjyrm #VidaPortfolio #VIGL

Proud to co-lead InduPro’s $85 million Series A financing as they leverage induced proximity to modulate disease biology towards next-generation therapeutics. This financing will enable the company to further refine the technology and to map and drug protein interactions in cancer and autoimmune disease. Congratulations, InduPro! Read more: https://bit.ly/3L2r7aR #VidaPortfolio

For the 9th straight year, Los Angeles Business Journal has recognized our Co-Founder and Senior Managing Director, Arie Belldegrun, MD, in the #LA500, a list that celebrates notable entrepreneurs and executives who influence Los Angeles. Arie’s visionary leadership, creativity and commitment continues to shape LA’s growing life sciences ecosystem. Congratulations on this well-deserved recognition! Learn more: https://bit.ly/3wS93wF

The Vida Ventures, LLC Boston team hosted a mixer for members of the Harvard Biotech Club yesterday, giving students an opportunity to learn more about the firm, valuable insights on life sciences investing and meet professionals in their field. Special thank you to our crimson alumns, Jill Goldstein, Mark Springel, Stefan Vitorovic and Arjun Goyal, M.D. for the photos. 
 
Thanks GSAS Harvard Biotech Club for stopping by!

Today, Aktis Oncology announced their collaboration with Eli Lilly and Company, leveraging Aktis’ proprietary miniprotein
discovery platform and Lily’s expertise to generate novel tumor-targeting
radiopharmaceuticals for cancer patients. Congratulations, Aktis, on this exciting milestone! Learn more: http://bit.ly/4bR83rr #VidaPortfolio

Metric
Company Name	VIDA Ventures
Symbol
MSH ID	COM:VIDAVENTURES
Market	PRIVATE
Sector	Financial Services & Finance
Industry	Venture Capital
Country	US
Stage
Employee Count	28
Website	vidaventures.com
LinkedIn	vida-ventures-llc
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

VIDA

COM:VIDAVENTURES

VIDA Ventures

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue